Fulgent Genetics

Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded on May 13, 2016 and is headquartered in Temple City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Fulgent Genetics surpasses revenue targets, eyes precision medicine growth

Fulgent Genetics delivered strong financial performance in 2022, exceeding revenue guidance and positioning for continued growth in 2023 across key business segments.
The company's strategic focus on precision medicine, oncology, and pharma services, coupled with a robust cash position, sets the stage for future expansion and innovation.
Challenges in margin improvement and reimbursement highlight areas for operational refinement, while opportunities in acquisitions and menu expansion offer avenues for sustained growth.

Fulgent Genetics reports robust Q1 revenue growth and strategic advancements

Fulgent Genetics delivered strong revenue growth in Q1 2023, with a focus on core business strength and promising developments in key drug candidates and business segments.
While facing challenges in operational efficiency and negative Adjusted EBITDA, the company maintains a strong cash position and is optimistic about future opportunities.
Strategic acquisitions, market expansion, and continued margin improvement are key areas of focus for Fulgent Genetics to drive sustained growth and profitability.

Fulgent Genetics reports record Q2 revenue and advances in cancer treatment

Fulgent Genetics (FLGT) delivered a strong performance in Q2 2023, with record core revenue and promising developments in cancer treatment.
The company's focus on innovation, operational efficiency, and margin improvement underscores a commitment to sustainable growth.
While facing challenges in cost management and competitive dynamics, Fulgent Genetics is well-positioned to capitalize on opportunities through technology and strategic initiatives.

Fulgent Genetics reports robust Q3 earnings, eyes growth in precision diagnostics

Fulgent Genetics demonstrated solid financial performance in Q3 2023, with strong core revenue and improved gross margins. The company continues to focus on precision diagnostics and therapeutic development, presenting growth opportunities. Challenges include fluctuations in Pharma services revenue and COVID-19 testing demand.

Fulgent Genetics surpasses Q4 revenue targets, eyes FDA regulatory landscape

Fulgent Genetics delivered strong Q4 results, exceeding revenue guidance and showcasing growth in core revenue.
The company faces challenges in BioPharma Services and Anatomic Pathology but is investing in operations and AI for improvement.
Opportunities lie in Precision Diagnostics growth, market share gains in carrier screening, and adapting to FDA oversight of laboratory developed tests.
Management's confidence in quality systems and readiness to pursue FDA approval for high-risk tests position Fulgent Genetics for regulatory changes.

Fulgent Genetics excels in Q1 2024 with strong revenue growth

Fulgent Genetics delivered strong Q1 results driven by precision diagnostics and therapeutic development progress.
While facing challenges in managing expenses, the company showcased financial discipline and innovation in new product launches.
With a focus on improving margins and capturing market opportunities, Fulgent Genetics aims for continued growth and profitability in 2024.

Fulgent Genetics reports robust Q2 revenue, invests in innovative treatments

Fulgent Genetics demonstrated solid revenue performance in Q2, driven by core business growth in key segments.
While facing profitability challenges, the company continues to invest in innovative treatments and technology.
Maintaining a strong cash position and focusing on strategic growth areas position Fulgent Genetics for future success.
Balancing cost management with revenue growth will be crucial for the company's financial health and long-term sustainability.

Fulgent Genetics reports robust Q3 earnings, eyes strategic growth opportunities

Fulgent Genetics demonstrated solid revenue growth and financial stability in Q3 2024.
The company's focus on precision diagnostics and therapeutic development shows promise for future growth.
Challenges lie in maintaining margins, managing expenses, and optimizing the VA contract's impact.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded by Ming Hsieh on May 13, 2016 and is headquartered in El Monte, CA.

Fulgent Genetics will partner with MedScan Laboratory to launch one of the market’s first COVID-19 tests based on comprehensive Next Generation Sequencing technology Fulgent Genetics will partner with MedScan Laboratory to launch one of the market’s first COVID-19 tests based on comprehensive Next Generation Sequencing technology

Fulgent Genetics Announces Launch of Next Generation Sequencing (NGS) Test to Detect Coronavirus Disease (COVID-19)

Fulgent Genetics, Inc. (FLGT) CEO Ming Hsieh on Q4 2019 Results - Earnings Call Transcript

TEMPLE CITY, Calif., March  10, 2020  (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a provider of comprehensive genetic testing and Next Generation Sequencing (“NGS”) solutions, today announced the promotion of Brandon Perthuis to chief commercial officer (CCO). Perthuis previously held the role of Vice President of Commercial Operations with Fulgent since joining the company in May of 2017. In his new role, Perthuis will continue to lead the company’s global sales organization and commercialization effort as the company focuses on both US and international expansion.

Fulgent Genetics Announces Promotion of Brandon Perthuis to Chief Commercial Officer

Beyond Meat

Semler Scientific

These three companies are all growing like gangbusters and have already reached profitability.

Hypergrowth or Profits? These 3 Stocks Don't Make You Choose

Fulgent Genetics' (FLGT) fourth-quarter 2019 earnings are likely to reflect top-line growth and elevated test volumes.

What's in Store for Fulgent Genetics (FLGT) Q4 Earnings?

FULGENT GENETIC (FLGT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FULGENT GENETIC (FLGT) Earnings Expected to Grow: Should You Buy?

Applied Therapeutics Inc

Community Health Systems

Enphase Energy

Tandem Diabetes Care

Better-than-expected earnings, positive development in the U.S.-China trade relationship, China stimulus measures, easing policies and slew of upbeat economic data buoyed the stocks.

5 Top-Ranked Stocks Beating the Market at Midway Q1

LeMaitre Vascular

We take a look at three small and promising healthcare companies across diagnostics, surgical products, and genetic testing.

3 Exciting Healthcare Stocks

Clovis Oncology

3D Systems

Mallinckrodt PLC

By Harry Boxer, TheTechTrader Here are three health stocks and one technology stock that are at or near key breakout points:

4 Stocks Looking Higher During Earnings Season

Algonquin Power & Utilities

Intellicheck

Sharps Compliance

Picking breakout stocks is one of the most favored methods for those utilizing an active investing approach since this strategy offers the scope of superlative returns.

4 Breakout Stocks for Explosive Returns: AQN, FLGT, IDN & SMED

Is  (FLGT) Outperforming Other Medical Stocks This Year?

Is FULGENT GENETIC (FLGT) Outperforming Other Medical Stocks This Year?

Cue Biopharma

EverBank Financial

Cassava Sciences Inc

Teekay Tankers

U.S. stocks rallied to attained fresh all-time highs in 2019, as the momentum continued in 2020. Here are five stocks that are poised to grow.

5 Stocks to Soar in 2020 After Solid Gains in 2019

Boot Barn Hlds

Sonic Automotive

Ultra Clean

Buy these five bets that reap solid returns from the Wall Street's rally in 2019 and are poised to yield high in the coming year.

2019 Hits a Purple Patch So Far: Check the Movers & Shakers

Brinker International

Hewlett Packard

Regeneron Pharmaceuticals

By following broker rating upgrades, an investor can easily find attractive stocks.

Buy These 5 Top-Ranked Stocks With Upgraded Broker Ratings.

TEMPLE CITY, Calif., Nov.  13, 2019  (GLOBE NEWSWIRE) -- Fulgent Genetics (NASDAQ: FLGT) (“Fulgent Genetics” or the “Company”), a provider of comprehensive genetic testing and Next Generation Sequencing (NGS) solutions, today announced the pricing of its previously announced underwritten public offering of 2,325,000 shares of its common stock at a public offering price of $11.25 per share, resulting in gross proceeds of approximately $26.2 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.

Fulgent Genetics Announces Pricing of Public Offering of Common Stock

TEMPLE CITY, Calif., Nov.  13, 2019  (GLOBE NEWSWIRE) -- Fulgent Genetics (NASDAQ: FLGT) (“Fulgent Genetics” or the “Company”), a provider of comprehensive genetic testing and Next Generation Sequencing (NGS) solutions, today announced that it has commenced an underwritten public offering of its common stock. In connection with this offering, Fulgent Genetics intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the public offering. All of the shares are being offered by Fulgent Genetics.  The Company currently intends to use the net proceeds from this offering for working capital and general corporate purposes.

Fulgent Genetics Announces Proposed Public Offering of Common Stock

Fulgent Genetics' Impressive Growth Acceleration Has Further To Run

Euronav

Orion Group Hlds

Find Strong Buy Stocks with this Filtered Zacks Rank 5 Stock Screener

Does FULGENT GENETIC (FLGT) have what it takes to be a top stock pick for momentum investors? Let's find out.

FULGENT GENETIC (FLGT) Is Up 68.12% in One Week: What You Should Know

FULGENT GENETIC (FLGT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Surging Earnings Estimates Signal Upside for FULGENT GENETIC (FLGT) Stock

Fulgent Genetics, Inc. (FLGT) CEO Ming Hsieh on Q3 2019 Results - Earnings Call Transcript

Ensign Group

Joint

NeoGenomics

Volitionrx Limited

These healthcare stocks are all worth a "buy" now. The healthcare sector will keep chugging along despite market volatility.

7 Next-Generation Healthcare Stocks to Buy

New line of at-home screening tests combines Fulgent’s advanced NGS solutions with actionable results and genetic counseling options for consumers New line of at-home screening tests combines Fulgent’s advanced NGS solutions with actionable results and genetic counseling options for consumers

Fulgent Genetics Launches Picture Genetics, a Consumer-Initiated Genetic Testing Offering

As of late, it has definitely been a great time to be an investor in Fulgent Genetics, Inc. (FLGT).

Fulgent Genetics, Inc. (FLGT) Shares March Higher, Can It Continue?

Fulgent Genetics, Inc. (FLGT) CEO Ming Hsieh on Q2 2019 Results - Earnings Call Transcript

News for Fulgent Genetics Stock (FLGT)